SCHEMBL13015082

SCHEMBL13015082

O=C(Nc1ccc(OC(F)(F)F)cc1)c1cnc(NC2CCNCC2)nc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.54
▸ SYK P43405 2/20 0.51
▸ CTSL P07711 1/20 0.49
▸ CTSB P07858 1/20 0.49
▸ CTSS P25774 1/20 0.49
▸ CTSK P43235 1/20 0.49
▸ NPC1 O15118 3/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ CNR2 P34972 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ TSHR P16473 1/20 0.44
▸ ATF1 P18846 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ ABL1 P00519 2/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13015051 0.87 CNR2 (0.53) CNR2ATF1NFKB1XPO1
SCHEMBL3770123 0.83 ALDH1A1 (0.49) EPHX1SYKNPC1HTTSMN1; SMN2
SCHEMBL3770097 0.78 CDK2 (0.46) SYKCNR2CDK1CDK4CCND1
SCHEMBL1862523 0.76 NFKB1 (0.74) NPC1MAPTMEN1KMT2AATF1
SCHEMBL5536264 0.71 EPHX1 (0.64) EPHX1SYKCTSLCTSBCTSS
SCHEMBL3767960 0.71 NR3C1 (0.60) NPC1HTTSMN1; SMN2MAPTMEN1
SCHEMBL541685 0.71 NFKB1 (0.65) CNR2ATF1NFKB1XPO1
SCHEMBL2718899 0.71 EPHX1 (1.00) EPHX1EPHX2
Hydrochloric Acid SCHEMBL411544 0.70 EPHX1 (0.63) EPHX1SYKCTSLCTSBCTSS
SCHEMBL736928 0.67 SYK (1.00) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 — — US disclosed
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 — — US disclosed
EP-2001867-B1 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-07-01 — — EP disclosed
WO-2007110340-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 — — WO disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 — — US disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives SSTR5, SSTR3, SSTR1 EPHX1 3253/4885SYK 1926/4885CTSL 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback